Aspira Pathlab & Diagnostics Ltd

Aspira Pathlab & Diagnostics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Aspira Pathlab & Diagnostics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 31 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Aspira Pathlab & Diagnostics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 July 2026, providing investors with an up-to-date perspective on its performance and outlook.

Aspira Pathlab & Diagnostics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 08 July 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Aspira Pathlab & Diagnostics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 June 2026, providing investors with the latest insights into the company’s performance and outlook.

Aspira Pathlab & Diagnostics Ltd is rated Sell by MarketsMOJO. This rating was last updated on 18 May 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 16 June 2026, providing investors with the most up-to-date insight into the stock’s fundamentals, valuation, financial trend, and technical outlook.

Aspira Pathlab & Diagnostics Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 01 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Surging past its previous peaks, Aspira Pathlab & Diagnostics Ltd reached a fresh 52-week high of Rs 133 on 29 Jun 2026, marking a remarkable rally of over 156% in the past year. This milestone comes amid a sustained 13-day winning streak, underscoring the stock's robust price momentum despite a broader market that has struggled to maintain gains.

Extending a remarkable rally that has spanned several months, Aspira Pathlab & Diagnostics Ltd surged to a fresh all-time high of Rs 132.96 on 29 May 2026, marking a significant milestone for the healthcare services micro-cap. This price level caps a stunning 156.7% gain over the past year, vastly outpacing the Sensex, which has declined 7.1% over the same period.

Surging to an all-time high of Rs 130 on 27 May 2026, Aspira Pathlab & Diagnostics Ltd has demonstrated remarkable price momentum, doubling from its 52-week low of Rs 49 within the past year. This rally stands out amid a broadly subdued market backdrop, underscoring the stock’s technical resilience and sustained buying interest.

Surging past its previous peaks, Aspira Pathlab & Diagnostics Ltd touched a fresh 52-week high of Rs 130 on 27 May 2026, marking a remarkable rally of over 135% from its low of Rs 49 in the past year. This milestone comes amid a sustained technical uptrend that has propelled the stock well above all key moving averages, signalling robust momentum in the healthcare services sector.

Extending a remarkable winning streak to 12 sessions, Aspira Pathlab & Diagnostics Ltd surged to a fresh all-time high of Rs 128.99 on 27 May 2026, marking a 102.21% gain over this period. This rally has significantly outpaced the Sensex, which declined 0.22% on the same day, underscoring the stock’s strong relative performance within the healthcare services sector.

Surging past its previous peaks, Aspira Pathlab & Diagnostics Ltd touched a fresh 52-week high of Rs 124.5 on 26 Jun 2026, marking a remarkable rally of over 95% in just 11 consecutive trading sessions. This momentum has propelled the stock well above all key moving averages, signalling robust technical strength amid a broadly recovering market backdrop.

Aspira Pathlab & Diagnostics Ltd has reached a significant milestone by touching its all-time high price of Rs.122.95 on 26 May 2026, marking a remarkable phase in the company’s market journey within the healthcare services sector.

Aspira Pathlab & Diagnostics Ltd has witnessed a significant shift in its valuation parameters, moving from an expensive to a risky territory as per recent assessments. Despite a robust price rally, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios, coupled with deteriorating profitability metrics, raise concerns about its price attractiveness relative to peers and historical benchmarks.

Surging past its previous peaks, Aspira Pathlab & Diagnostics Ltd touched a fresh 52-week high of Rs 118.9 on 25 Jun 2026, marking a remarkable rally of 113.10% over the past year. This milestone comes amid a sustained 10-day winning streak, underscoring the stock’s robust price momentum and technical alignment.